Metformin and cancer mortality
The author analyses recent publications supporting the ability of metformin to decrease the risk of cancer morbidity and mortality in patients with type 2diabetes mellitus. Pre-history of the problem (including the use of biguanides for metabolic rehabilitation of oncological patients), the role of...
Enregistré dans:
Auteur principal: | Lev Mikhaylovich Bershteyn |
---|---|
Format: | article |
Langue: | EN RU |
Publié: |
Endocrinology Research Centre
2010
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/05da729af1a04fbb8decb7c01a66bd6a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Hormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancer
par: Lev Mikhaylovich Bershteyn, et autres
Publié: (2014) -
Multidimensional effects of metformin in patients with type 2 diabetes
par: Lyudmila A. Ruyatkina, et autres
Publié: (2017) -
Efficacy and safety of metformin for the treatment of gestational diabetes: a new approach to the problem
par: Anna I. Sazonova, et autres
Publié: (2016) -
Diabetes, obesity and cancer: risk and anti-risk factors
par: Lev Mikhaylovich Bershteyn
Publié: (2012) -
Evaluation of fixed dose combination of glimepiride and metformin in patients with type 2 diabetes. Results of Russian observational study
par: Natalya Vladislavovna Zaytseva, et autres
Publié: (2015)